Helix BioPharma Corp. (TSE:HBP - Get Free Report)'s share price hit a new 52-week high on Monday . The stock traded as high as C$1.48 and last traded at C$1.48, with a volume of 136 shares trading hands. The stock had previously closed at C$1.45.
Helix BioPharma Stock Performance
The company has a 50 day moving average of C$1.18 and a two-hundred day moving average of C$0.99. The stock has a market cap of C$116.09 million, a PE ratio of -1.48 and a beta of -0.45.
Helix BioPharma Company Profile
(
Get Free Report)
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
Featured Stories
Before you consider Helix BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Helix BioPharma wasn't on the list.
While Helix BioPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
